Overview
Clinical Images
Documents
Training
HEALTH NEWS HIGHLIGHT:
FDA Guidelines Require
Breast Density Reporting
Hologic has more solutions that help radiologists identify and detect breast cancer in women with dense breasts.
Hologic and Bayer join forces to provide a coordinated Contrast-Enhanced Mammography solution
A better 3D™ breast screening experience – for everyone.
The 3Dimensions system is designed to provide higher quality 3D images for radiologists, a more comfortable mammography experience for patients and enhanced workflow for technologists. Discover how sharper images and smarter technologies continue to help find invasive cancers regardless of age or breast density.1-6
Designed to be one of the fastest, highest resolution breast tomosynthesis systems available.
The 3Dimensions mammography system matches the unrivaled performance of our Hologic 3D™
mammogram, which is more accurate than conventional 2D mammograms, detecting 20%-65% more invasive breast cancers.1-8 Breakthrough improvements transform the patient experience without compromising speed or accuracy.
Better visibility
Designed to improve visibility of fine details for greater diagnostic confidence.*
More comfortable
Clinically proven to deliver a more comfortable mammogram.7
Improves the patient experience with a curved compression surface that mirrors the shape of the breast for a more even compression
More efficient
Enables technologists to conduct fast, efficient exams and accelerate reading time to streamline workflow.**
Video Resources
Beyond Screening: Breast Cancer Index® Test
As breast cancer survivors continue to get regular screenings throughout survivorship, understanding long term treatment plans is also essential. The Breast Cancer Index® test helps determine if a patient with HR+, early-stage breast cancer is likely to benefit from extending endocrine therapy to 10 years, or if she can stop at the 5-year mark and avoid potential side effects.
Product Images
* is compared to 2D alone
** FDA PMA Approval P080003/S006
- FDA submissions P080003, P080003/S001, P080003/S004, P080003/S005.
- Friedewald SM, Rafferty EA, Rose SL, et al. Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA. 2014 Jun 25;311(24):2499-507.
- Zuckerman SP, Conant EF, Keller BM, et al. Implementation of Synthesized Two-dimensional Mammography in a Population-based Digital Breast Tomosynthesis Screening Program. Radiology. 2016 Dec; 281(3):730-736.
- Skaane P, Bandos A, Eben EB, et al. Two-view digital breast tomosynthesis screening with synthetically reconstructed projection images: comparison with digital breast tomosynthesis with full-field digital mammographic images. Radiology. 2014 Jun; 271(3):655-63.
- Bernardi D, Macaskill P, Pellegrini M, et al. Breast cancer screening with tomosynthesis (3D mammography) with acquired or synthetic 2D mammography compared with 2D mammography alone (STORM-2): a population-based prospective study. Lancet Oncol. 2016 Aug;17(8):1105-13.
- McDonald ES, Oustimov A, Weinstein SP, et al. Effectiveness of Digital Breast Tomosynthesis Compared With Digital Mammography: Outcomes Analysis From 3 Years of Breast Cancer Screening. JAMA Oncol. 2016 Jun 1;2(6):737 43.
- Rafferty EA, Durand MA, Conant EF, et al. Breast Cancer Screening Using Tomosynthesis and Digital Mammography in Dense and Nondense Breasts. JAMA. 2016 Apr 26;315(16):1784-6.
- Smith, A. Improving Patient Comfort in Mammography. Hologic WP-00019 Rev 003 (2017)
Bayer and the Bayer Cross are trademarks owned by and/or registered to Bayer in the U.S. and/or other countries.
